News >

FDA Halts Enrollment on Venetoclax Myeloma Trials

Jason M. Broderick @jasoncology
Published: Tuesday, Mar 19, 2019

The FDA has placed a partial clinical hold on all clinical trials examining venetoclax (Venclexta) in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche).

The clinical hold does not affect any of the FDA-approved indications for venetoclax, which include the treatment of patients with chronic lymphocytic leukemia and acute myeloid leukemia. The hold also does not impact clinical studies of the BCL-2 inhibitor for patients with malignancies other than myeloma.
AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program. AbbVie. Published March 19, 2019. Accessed March 19, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication